These FDA-approved medications for chronic weight management work by slowing gastric emptying and affecting appetite-regulating pathways, which can trigger gastrointestinal symptoms
Only if the weight loss is prescribed to treat a documented medical condition, such as clinical obesity with a comorbidity, cardiovascular disease, or hypertension
Acknowledgements This work was supported by a project (HI21C0694, Development of treatment for intractable skin diseases using low-molecular compounds with enhanced Wnt/beta-catenin) funded by the Ministry of Health and Welfare, Republic of Korea and by the National Research Foundation of Korea(KRF) grant funded by the Korea government(MSIT) (RS-2025-16072747)
HIDRADENITIS SUPPURATIVA Dosing for ADULTS & ADOLESCENTS 12 years, 60 kg (132 lbs) Induction Dose Option #1 HUMIRA Pen 80 mg/0.8 mL (2) - NDC: 0074-0214-02 HUMIRA Pen 40 mg/0.4 mL (2) - NDC: 0074-0554-02 NDC: 0074-0214-02 DAY 1 2 x 80 mg (160 mg) or one 80 mg injection on Days 1 and 2 NDC: 0074-0554-02 DAY 15 2 x 40 mg (80 mg) OR Induction Dose Option #2 HUMIRA Pen 40 mg/0.4 mL (2) - NDC: 0074-0554-02 X 3 cartons NDC: 0074-0554-02 (2) DAY 1 4 x 40 mg (160 mg) or two 40 mg injections on Days 1 and 2 NDC: 0074-0554-02 DAY 15 2 x 40 mg (80 mg) Please see package insert for induction dosing regimen
Common GLP-1 medications include: Ozempic and Wegovy (semaglutide) Mounjaro and Zepbound (tirzepatide) These medications are typically taken as weekly injections under medical supervision
